IRIS

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018) / Ascierto, P. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - 19:10(2018), pp. E509-E509.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018)

Ascierto P
2018
2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018) / Ascierto, P. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - 19:10(2018), pp. E509-E509.
1.7 Commento, erratum, replica e simili
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014539
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact